Juniper Pharmaceuticals, Inc. (JNP)

günstiger Titel,profitabel,und grade auf All-Time -low,gute Pipeline ....

der Typ im yahoo Board scheint mehr zu wissen,immerhin bewegt sich die Aktie seit 2012 kaum noch und ist normalerweise viel zu billig .....

hm ?

würd ich aber das Geschreibsel von dem Typen auch nicht überbewerten,er ist alleine im Board,sieht mir ganz nach bezahlter Basher aus,ich glaube eher die Aktie ist auf aktuellem Niveau ein guter Kauf .....

Renaissance Technologies LLC boosted its position in Juniper Pharmaceuticals Inc (NASDAQ:JNP) by 7.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 254,300 shares of the specialty pharmaceutical company’s stock after buying an additional 17,900 shares during the period. Renaissance Technologies LLC owned approximately 2.35% of Juniper Pharmaceuticals worth $1,424,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in JNP. Stonepine Capital Management LLC increased its stake in Juniper Pharmaceuticals by 31.3% in the fourth quarter. Stonepine Capital Management LLC now owns 228,392 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after buying an additional 54,425 shares during the period. Eagle Global Advisors LLC increased its stake in Juniper Pharmaceuticals by 29.3% in the third quarter. Eagle Global Advisors LLC now owns 44,442 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 10,070 shares during the period. Spark Investment Management LLC increased its stake in Juniper Pharmaceuticals by 11.3% in the third quarter. Spark Investment Management LLC now owns 48,400 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 4,900 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Juniper Pharmaceuticals by 26.3% in the third quarter. Wells Fargo & Company MN now owns 145,586 shares of the specialty pharmaceutical company’s stock worth $808,000 after buying an additional 30,286 shares during the period. Hedge funds and other institutional investors own 33.12% of the company’s stock.  

A number of institutional investors have recently bought and sold shares of JNP. Goldman Sachs Group Inc. bought a new position in Juniper Pharmaceuticals during the first quarter valued at about $100,000. KCG Holdings Inc. bought a new position in Juniper Pharmaceuticals during the first quarter valued at about $112,000. TFS Capital LLC boosted its position in Juniper Pharmaceuticals by 87.0% in the first quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 14,707 shares in the last quarter. Acadian Asset Management LLC boosted its position in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares in the last quarter. Finally, Eagle Global Advisors LLC boosted its position in Juniper Pharmaceuticals by 29.3% in the third quarter. Eagle Global Advisors LLC now owns 44,442 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 10,070 shares in the last quarter. Institutional investors and hedge funds own 33.12% of the company’s stock.

Juniper Pharmaceuticals (NASDAQ:JNP) remained flat at $4.15 during trading on Tuesday. The stock had a trading volume of 17,799 shares. Juniper Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $8.00. The firm’s 50 day moving average is $4.22 and its 200 day moving average is $4.94. The company has a market capitalization of $45.00 million, a P/E ratio of 7.35 and a beta of 0.25.

Juniper Pharmaceuticals (NASDAQ:JNP) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.04. The business had revenue of $11.25 million during the quarter, compared to analysts’ expectations of $11.27 million. Juniper Pharmaceuticals had a negative return on equity of 9.68% and a negative net margin of 7.44%. Equities analysts forecast that Juniper Pharmaceuticals will post ($0.45) earnings per share for the current year.  

Analysts Set Juniper Pharmaceuticals, Inc. (JNP) Price Target at $12.00
June 21st, 2017 - By Scott Moore - 0 comments

Juniper Pharmaceuticals logoShares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have earned a consensus rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.00.

A number of analysts have recently issued reports on JNP shares. TheStreet raised shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a report on Wednesday, April 12th. HC Wainwright reiterated a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Friday, May 5th. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 6th. Finally, ValuEngine cut shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd.

www.fiercepharma.com/manufacturing/...juniper-pharmaceuticals